卵巢癌裸鼠皮下移植瘤和腹水瘤模型导向治疗的研究  

The study of target therapy by monocloclonalantibody agaiust ovarian carcinoma conjugated with,Iiposome and adriamycin.

作　　者：李文锦[1] 钱和年[1] 吕文英[1] 刘燕妮[1] 贾鉴慧 崔恒[1] 冯捷[1] 颜士杰 王建六[1] 

机构地区：[1]北京医科大学附属人民医院妇科肿瘤研究室,辽宁省肿瘤医院,安徽医科大学第一医院

出　　处：《中华妇产科杂志》1994年第5期296-298,共3页Chinese Journal of Obstetrics and Gynecology

摘　　要：采用抗卵巢癌单克隆抗体（单抗）－脂质体－阿霉素交联物（ＭＬＡ）、阿霉素、ＣＯＣ１６６－９单抗、正常鼠ＩｇＧ脂质体阿霉素交联物（ＮＭＬＡ）及生理盐水，对卵巢癌细胞系ＳＫＯＶ＿３接种的２４只裸鼠皮下移植瘤模型及１６只腹水瘤模型分别进行导向及非导向治疗，观察对比疗效。皮下移植瘤模型以肿瘤生长大小、腹水瘤模型以裸鼠死亡时间为观察指标，判断治疗效果。结果：各治疗药物对肿瘤生长均有抑制作用，以ＭＬＡ导向治疗的效果最好。说明导向治疗是有价值和发展前景的疗法。onjugates of monoclonal antibody(MAb)andadriamycin entrapped in liposome(M LA) were pre-pared by COC166-9.The MAb against ovarianserous adenocarcinoma was generated in our labora-tory .Targer therapies were done in nude mice modelwith subcutaneous tumor xenografts in 24 and asciticcarcinoma in 16 by M LA. The results demonstratedthat M LA group presented the best therapeutic effectthan all the other groups,which gave a very helpfulclue to clinicaI target therapy of ovarian carcinoma inthe future.

关 键 词：卵巢肿瘤 单克隆抗体 导向疗法 

分 类 号：R737.310.5[医药卫生—肿瘤]